Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC

NEOS Investment Management LLC increased its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 40.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 162,186 shares of the company’s stock after buying an additional 46,755 shares during the quarter. NEOS Investment Management LLC owned about 0.19% of Immunome worth $1,899,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after acquiring an additional 14,398 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Immunome in the 2nd quarter valued at about $428,000. Brighton Jones LLC acquired a new position in Immunome during the 2nd quarter valued at about $98,000. Y Intercept Hong Kong Ltd bought a new position in Immunome in the 2nd quarter worth about $793,000. Finally, Teacher Retirement System of Texas increased its stake in shares of Immunome by 6.8% in the second quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock valued at $172,000 after purchasing an additional 1,188 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Clay B. Siegall acquired 4,729 shares of Immunome stock in a transaction dated Tuesday, December 30th. The stock was acquired at an average cost of $21.15 per share, with a total value of $100,018.35. Following the purchase, the chief executive officer directly owned 665,254 shares in the company, valued at $14,070,122.10. The trade was a 0.72% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Philip Tsai purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was bought at an average price of $20.49 per share, with a total value of $204,900.00. Following the transaction, the insider directly owned 43,300 shares in the company, valued at $887,217. This trade represents a 30.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 68,518 shares of company stock worth $1,453,958. Insiders own 7.69% of the company’s stock.

Immunome Trading Down 2.9%

NASDAQ:IMNM opened at $21.50 on Friday. The company has a 50-day moving average of $22.73 and a 200-day moving average of $16.86. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of -7.29 and a beta of 2.32. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $27.65.

Analyst Ratings Changes

Several analysts have weighed in on the company. Stephens lifted their target price on Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research note on Monday, November 17th. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Immunome in a research report on Thursday, January 15th. Leerink Partners set a $40.00 target price on shares of Immunome in a research note on Monday, December 15th. Evercore boosted their price target on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.75.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.